...
首页> 外文期刊>Heart and vessels: An international journal >Sutureless aortic bioprosthesis valve implantation and bicuspid valve anatomy: an unsolved dilemma?
【24h】

Sutureless aortic bioprosthesis valve implantation and bicuspid valve anatomy: an unsolved dilemma?

机译:无缝主动脉生物瓣膜植入术和二尖瓣解剖:未解决的难题?

获取原文
获取原文并翻译 | 示例
           

摘要

Interest is growing in the clinical use of sutureless (SU) valves. However, indications in some anatomical sub-settings, like bicuspid aortic valves (BAV), have been so far limited. We discuss herein our initial experience with the implantation of the 3f Enable SU bioprosthesis in patients with a BAV. Patients with a BAV were selected in our unit between March 2011 and September 2014 for a SU 3f Enable valve implantation. Twenty of the 198 patients who underwent a 3f Enable valve implantation in our unit had a BAV. Procedural success was 100 %, but reclamping was necessary in one (5 %) case. Median size of implanted bioprosthesis was 23 mm. After a mean follow-up of 13.8 +/- 10.7 months, survival was 100 %. Two patients (10 %) showed an immediate grade 1 paravalvular leak (PVL) that progressed to grade 2 and 3+ (moderate/severe), respectively, during follow-up. Type of bicuspidy (Sievers classification) in these two patients was 0 and intraoperatively aortic annuli admitted the 25 mm calibrator. Among the 18 patients without PVL, no one had a type 0 large BAV. At 1 year, implantation of the 3f Enable SU bioprosthesis appears to be safe in patients with BAV type I and II, while in type 0 use of the SU valve seems to be safe only if the annular diameter is < 25 mm. Larger studies are necessary to confirm our findings in order to clarify the indications for SU technology in the subset of bicuspid patients.
机译:对无缝合(SU)瓣膜的临床使用的兴趣正在增长。但是,到目前为止,在某些解剖学子环境中的适应症(例如二尖瓣主动脉瓣(BAV))受到了限制。我们在此讨论在BAV患者中植入3f Enable SU生物假体的初步经验。我们在2011年3月至2014年9月期间选择了BAV患者进行SU 3f Enable瓣膜植入术。在我们部门接受3f Enable瓣膜植入术的198位患者中,有20位患有BAV。手术成功率为100%,但在一例(5%)的情况下必须再次钳夹。植入的生物假体的中位大小为23 mm。在平均随访13.8 +/- 10.7个月后,存活率为100%。两名患者(10%)表现为立即1级瓣周漏(PVL),在随访期间分别进展为2级和3+级(中度/重度)。这两名患者的双尖瓣类型(Sievers分类)为0,术中主动脉瓣环接纳25 mm校准器。在18例无PVL的患者中,没有人患有0型大BAV。在1年时,对于I型和II型BAV患者,植入3f Enable SU生物假体似乎是安全的,而在0型中,仅当环形直径小于25 mm时,使用SU瓣膜才是安全的。为了阐明我们的发现,以澄清双尖瓣患者亚型SU技术的适应症,有必要进行更大的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号